ud cg 212 cl has been researched along with Heart Failure in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasanuki, H; Matsuda, N; Naganuma, M; Shiga, T; Tatami, S; Wakaumi, M | 1 |
| Brogden, RN; Fitton, A | 1 |
| Bethke, T; Klimkiewicz, A; Kohl, C; Mehl, H; Mende, U; Meyer, W; Neumann, J; Schmitz, W; Scholz, H; von der Leyen, H | 1 |
| Böhm, M; Erdmann, E; Schwinger, RH; Ungerer, M | 1 |
| Brand, HJ; Hagemeijer, F; Roth, W | 2 |
| Bernard, R; Dresse, A; Goethals, H; Liebens, I; Renard, M; Walter, M | 1 |
1 review(s) available for ud cg 212 cl and Heart Failure
| Article | Year |
|---|---|
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Clinical Trials as Topic; Drug Interactions; Electrophysiology; Heart Failure; Hemodynamics; Humans; Intestinal Absorption; Liver; Myocardium; Phosphodiesterase Inhibitors; Pyridazines | 1994 |
2 trial(s) available for ud cg 212 cl and Heart Failure
| Article | Year |
|---|---|
Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure.
Topics: Administration, Oral; Cardiomyopathy, Dilated; Cardiotonic Agents; Heart Failure; Humans; Natriuretic Peptide, Brain; Pyridazines | 2003 |
Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses.
Topics: Aged; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Double-Blind Method; Heart Failure; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Pulmonary Circulation; Pyridazines; Random Allocation; Vascular Resistance | 1988 |
4 other study(ies) available for ud cg 212 cl and Heart Failure
| Article | Year |
|---|---|
Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.
Topics: Adult; Calcium; Chromatography, DEAE-Cellulose; Electric Stimulation; Female; Heart; Heart Failure; Humans; Imidazoles; In Vitro Techniques; Isoenzymes; Isoproterenol; Male; Middle Aged; Milrinone; Myocardial Contraction; Myocardium; Ouabain; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Pyridones | 1991 |
Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.
Topics: Adult; Binding, Competitive; Cardiotonic Agents; Electric Stimulation; Guanylyl Imidodiphosphate; Heart; Heart Failure; Humans; Imidazoles; In Vitro Techniques; Membranes; Milrinone; Myocardium; Piperazines; Pyridazines; Pyridones; Quinuclidinyl Benzilate; Receptors, Cholinergic; Receptors, Purinergic; Xanthines | 1990 |
Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
Topics: Aged; Blood Chemical Analysis; Blood Pressure; Cardiac Output; Cardiotonic Agents; Exercise Test; Female; Glucose Tolerance Test; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyridazines; Time Factors | 1989 |
Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Topics: Administration, Oral; Aged; Cardiotonic Agents; Cardiovascular System; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyridazines; Time Factors | 1989 |